GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MEX:BMRN) » Definitions » Shiller PE Ratio

Biomarin Pharmaceutical (MEX:BMRN) Shiller PE Ratio : (As of May. 04, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Biomarin Pharmaceutical Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomarin Pharmaceutical Shiller PE Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Shiller PE Ratio Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biomarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biomarin Pharmaceutical's Shiller PE Ratio

For the Biotechnology subindustry, Biomarin Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Shiller PE Ratio falls into.


;
;

Biomarin Pharmaceutical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biomarin Pharmaceutical's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Biomarin Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=19.435/134.9266*134.9266
=19.435

Current CPI (Mar. 2025) = 134.9266.

Biomarin Pharmaceutical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 -8.002 100.684 -10.723
201509 -10.139 100.392 -13.627
201512 6.706 99.792 9.067
201603 -8.779 100.470 -11.790
201606 -47.713 101.688 -63.309
201609 -4.254 101.861 -5.635
201612 -10.927 101.863 -14.474
201703 -1.695 102.862 -2.223
201706 -3.796 103.349 -4.956
201709 -1.270 104.136 -1.646
201712 -5.892 104.011 -7.643
201803 -4.724 105.290 -6.054
201806 -1.768 106.317 -2.244
201809 -130.935 106.507 -165.873
201812 -0.589 105.998 -0.750
201903 -6.207 107.251 -7.809
201906 -4.034 108.070 -5.037
201909 5.923 108.329 7.377
201912 1.509 108.420 1.878
202003 10.317 108.902 12.783
202006 -3.693 108.767 -4.581
202009 88.585 109.815 108.842
202012 2.387 109.897 2.931
202103 1.840 111.754 2.222
202106 1.393 114.631 1.640
202109 -4.112 115.734 -4.794
202112 -6.564 117.630 -7.529
202203 12.544 121.301 13.953
202206 3.018 125.017 3.257
202209 -0.805 125.227 -0.867
202212 -0.026 125.222 -0.028
202303 4.867 127.348 5.157
202306 4.972 128.729 5.211
202309 3.658 129.860 3.801
202312 1.867 129.419 1.946
202403 7.634 131.776 7.817
202406 10.076 132.554 10.256
202409 10.830 133.029 10.984
202412 13.348 133.157 13.525
202503 19.435 134.927 19.435

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomarin Pharmaceutical  (MEX:BMRN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biomarin Pharmaceutical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.